Interleukin-6-Mediated Inflammation May Cause Methotrexate-Induced Leukoencephalopathy

Area of Science:

• Neuroscience
• Oncology
• Immunology

Background:

• Methotrexate (MTX) is a crucial chemotherapy agent for childhood leukemia.
• MTX-induced leukoencephalopathy (MTX-LE) is a serious neurological complication.
• The exact mechanisms driving MTX-LE remain unclear.

Purpose of the Study:

• To investigate differences in cerebrospinal fluid (CSF) cytokine/chemokine profiles.
• To compare profiles between MTX-LE and posterior reversible encephalopathy syndrome (PRES) in children with leukemia.
• To identify potential biomarkers for MTX-LE pathogenesis.

Main Methods:

• Analyzed CSF cytokine and chemokine concentrations using multiplex assays.
• Included pediatric patients with acute leukemia and MTX-LE, PRES, no neurological complications, or acute encephalopathy.
• Measured a panel of 15 key inflammatory mediators.

Main Results:

• CSF IL-6 concentrations were significantly higher in children with MTX-LE compared to other groups.
• No significant differences were observed in other measured cytokines/chemokines across groups.
• This highlights a specific inflammatory signature in MTX-LE.

Conclusions:

• Elevated CSF IL-6 may play a role in the development of MTX-induced leukoencephalopathy.
• IL-6 could be a potential therapeutic target for preventing or treating MTX-LE.
• Further research is warranted to confirm IL-6's pathogenic role.